Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Am J Public Health. 2011 Apr;101(4):602-9. doi: 10.2105/AJPH.2010.300027. Epub 2011 Jan 13.

Health advocacy organizations and the pharmaceutical industry: an analysis of disclosure practices.

Author information

  • 1Division of Sociomedical Sciences, Mailman School of Public Health, Columbia University, New York, NY, USA. smr4@columbia.edu

Abstract

Health advocacy organizations (HAOs) are influential stakeholders in health policy. Although their advocacy tends to closely correspond with the pharmaceutical industry's marketing aims, the financial relationships between HAOs and the pharmaceutical industry have rarely been analyzed. We used Eli Lilly and Company's grant registry to examine its grant-giving policies. We also examined HAO Web sites to determine their grant-disclosure patterns. Only 25% of HAOs that received Lilly grants acknowledged Lilly's contributions on their Web sites, and only 10% acknowledged Lilly as a grant event sponsor. No HAO disclosed the exact amount of a Lilly grant. As highly trusted organizations, HAOs should disclose all corporate grants, including the purpose and the amount. Absent this disclosure, legislators, regulators, and the public cannot evaluate possible conflicts of interest or biases in HAO advocacy.

Comment in

PMID:
21233424
[PubMed - indexed for MEDLINE]
PMCID:
PMC3052325
Free PMC Article

Images from this publication.See all images (1)Free text

FIGURE 1
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Atypon Icon for PubMed Central
    Write to the Help Desk